{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:14:40Z","timestamp":1779203680728,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40123-025-01159-2","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T23:06:07Z","timestamp":1748387167000},"page":"1551-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Masayuki","family":"Ohnaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusaburo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Nagamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Maio-Twofoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Karcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"9","key":"1159_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"1159_CR2","unstructured":"Tietz J, Spohn G, Schmid G, Konrad J, Jampen S, Maurer P, Schmidt A, Escher D. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders. ARVO annual meeting abstract 2015: IOVS; 2015."},{"issue":"1","key":"1159_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"1","key":"1159_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89\u201399.","journal-title":"Ophthalmology"},{"key":"1159_CR5","doi-asserted-by":"crossref","unstructured":"Baumal CR, S\u00f8rensen TL, Karcher H, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol. 2022.","DOI":"10.1111\/aos.15242"},{"issue":"4","key":"1159_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/2474126420930863","volume":"4","author":"AJ Witkin","year":"2020","unstructured":"Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269\u201379.","journal-title":"J Vitreoretin Dis"},{"issue":"7","key":"1159_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050\u20139.","journal-title":"Ophthalmology"},{"issue":"5","key":"1159_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","volume":"13","author":"MA Zarbin","year":"2024","unstructured":"Zarbin MA, MacCumber MW, Karcher H, et al. Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae Registry. Ophthalmol Ther. 2024;13(5):1357\u201368.","journal-title":"Ophthalmol Ther"},{"key":"1159_CR9","doi-asserted-by":"crossref","unstructured":"Liegl RG, Karcher H, Chetty-Mhlanga S, et al. The treatment patterns with brolucizumab in Germany (REALIZE) study: a retrospective cohort study based on longitudinal prescription data. Ophthalmol Ther. 2022.","DOI":"10.1007\/s40123-022-00596-7"},{"issue":"1","key":"1159_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40942-023-00445-0","volume":"9","author":"JM Coney","year":"2023","unstructured":"Coney JM, Zubricky R, Sinha SB, et al. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. Int J Retina Vitreous. 2023;9(1):8.","journal-title":"Int J Retina Vitreous"},{"key":"1159_CR11","doi-asserted-by":"crossref","unstructured":"Fukuda Y, Sakurada Y, Matsubara M, et al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines. 2021;9(9).","DOI":"10.3390\/biomedicines9091164"},{"issue":"5","key":"1159_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000526044","volume":"245","author":"J Hoshino","year":"2022","unstructured":"Hoshino J, Matsumoto H, Mukai R, et al. Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization: comparison of short-term outcomes. Ophthalmologica. 2022;245(5):413\u201320.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1159_CR13","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41598-024-52747-4","volume":"14","author":"S Inoda","year":"2024","unstructured":"Inoda S, Takahashi H, Takahashi R, et al. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients. Sci Rep. 2024;14(1):2451.","journal-title":"Sci Rep"},{"key":"1159_CR14","unstructured":"Kishimoto M. One-year results of switching to brolucizumab in exudative age-related macular degeneration. ARVO 20222022."},{"issue":"6","key":"1159_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","volume":"260","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro T, Tanaka K, Itagaki K, et al. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2022;260(6):1857\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1159_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10384-022-00922-3","volume":"66","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Koizumi H, Tamashiro T, et al. Short-term results for brolucizumab in treatment-na\u00efve neovascular age-related macular degeneration: a Japanese multicenter study. Jpn J Ophthalmol. 2022;66(4):379\u201385.","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"1159_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000524096","volume":"245","author":"C Regillo","year":"2022","unstructured":"Regillo C, Singh R, Hamilton R, et al. Fluid control in neovascular age-related macular degeneration with brolucizumab: an analysis of the HAWK and HARRIER phase 3 trials. Ophthalmologica. 2022;245(5):403\u201312.","journal-title":"Ophthalmologica"},{"key":"1159_CR18","doi-asserted-by":"crossref","unstructured":"Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: The REBA Study. J Clin Med. 2021;10(13).","DOI":"10.3390\/jcm10132758"},{"key":"1159_CR19","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.2147\/OPTH.S328160","volume":"15","author":"D Chakraborty","year":"2021","unstructured":"Chakraborty D, Maiti A, Sheth JU, et al. Brolucizumab in neovascular age-related macular degeneration\u2014Indian real-world experience: The BRAILLE Study. Clin Ophthalmol. 2021;15:3787\u201395.","journal-title":"Clin Ophthalmol"},{"key":"1159_CR20","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.2147\/OPTH.S376199","volume":"16","author":"M Giunta","year":"2022","unstructured":"Giunta M, Gauvin Meunier LP, Nixon D, et al. Early Canadian real-world experience with brolucizumab in anti-vascular endothelial growth factor-experienced patients with neovascular age-related macular degeneration: a retrospective chart review. Clin Ophthalmol. 2022;16:2885\u201394.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1159_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/IAE.0000000000003349","volume":"42","author":"PU Dugel","year":"2022","unstructured":"Dugel PU, Jhaveri CD, Chakravarthy U, et al. Effect of retinal thickness variability on visual outcomes and fluid persistence in neovascular age-related macular degeneration: a post hoc analysis of the HAWK and HARRIER studies. Retina. 2022;42(3):511\u20138.","journal-title":"Retina"},{"issue":"1","key":"1159_CR22","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1038\/s41598-022-10578-1","volume":"12","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Hoshino J, Mukai R, et al. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12(1):8195.","journal-title":"Sci Rep"},{"issue":"6","key":"1159_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10384-022-00940-1","volume":"66","author":"Y Kitajima","year":"2022","unstructured":"Kitajima Y, Maruyama-Inoue M, Ikeda S, et al. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66(6):511\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1159_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10384-022-00908-1","volume":"66","author":"H Ota","year":"2022","unstructured":"Ota H, Takeuchi J, Nakano Y, et al. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Jpn J Ophthalmol. 2022;66(3):278\u201384.","journal-title":"Jpn J Ophthalmol"},{"key":"1159_CR25","doi-asserted-by":"crossref","unstructured":"Haensli C, Pfister IB, Garweg JG. Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes. J Clin Med. 2021;10(12).","DOI":"10.3390\/jcm10122666"},{"issue":"2","key":"1159_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00417-022-05793-5","volume":"261","author":"T Ueda-Consolvo","year":"2023","unstructured":"Ueda-Consolvo T, Tanigichi A, Numata A, et al. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):345\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1159_CR27","doi-asserted-by":"publisher","first-page":"13152","DOI":"10.1038\/s41598-021-92567-4","volume":"11","author":"S Honda","year":"2021","unstructured":"Honda S, Yanagi Y, Koizumi H, et al. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11(1):13152.","journal-title":"Sci Rep"},{"issue":"1","key":"1159_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/13696998.2021.1971416","volume":"24","author":"JF Korobelnik","year":"2021","unstructured":"Korobelnik JF, Delcourt C, Creuzot-Garcher C, et al. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. J Med Econ. 2021;24(1):1087\u201397.","journal-title":"J Med Econ"},{"issue":"7","key":"1159_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","volume":"106","author":"Y Ogura","year":"2022","unstructured":"Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1159_CR30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/IAE.0000000000004009","volume":"44","author":"S Inoda","year":"2024","unstructured":"Inoda S, Takahashi H, Maruyama-Inoue M, et al. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: a multicenter age-related macular degeneration study. Retina. 2024;44(4):714\u201322.","journal-title":"Retina"},{"issue":"4","key":"1159_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302295","volume":"19","author":"K Hirono","year":"2024","unstructured":"Hirono K, Maruyama-Inoue M, Yanagi Y, et al. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration. PLoS ONE. 2024;19(4): e0302295.","journal-title":"PLoS ONE"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01159-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01159-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:59:08Z","timestamp":1757174348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01159-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01159-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to the missing of supplementary information. Now, the supplementary files are updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masayuki Ohnaka: Speaker (Bayer, Chugai, Novartis, Santen and Senju); Yoichi Sakurada: None; Atsushi Hayashi: Research (Nitto medic, Senju, Bayer, Kowa, Chugai, Alcon, R. E. medical, AMO Japan, AbbVie, Mitsubishi Tanabe Pharma, Santen, Siemens, Tsumura, and Ellex), Funding (AMO Japan, Alcon, Hoya, and Santen). Kazuaki Kadonosono: Funding (Alcon, Chugai, Hoffman-La Roche, Hoya, Kowa, Kyowa medical, R.E. Medical Santen, Senju); Hitoshi Ohno: Funding (Allergan Japan, Senju, Novartis, Bayer for clinical trial); Ryusaburo Mori: Speaker (Bayer, Senju, Chugai, Santen, Novartis, Boehringer Ingelheim, Kyowa Kirin); Hidetaka Matsumoto: Speaker (Novartis, Chugai, Bayer, Santen, and Senju), Research (Novartis and Bayer); Ippei Nagamori: Novartis employee; Yuki Murata: Novartis employee; Tina Maio-Twofoot: Novartis employee; Helene Karcher: Philip Morris Products S.A., Neuchatel, Switzerland. Ex-Novartis employee and shareholder; Hidenori Takahashi: Funding (Kyowa Kirin, Novartis, Bayer, and Linical), Personal interest (DeepEyeVision), Consultant (Boehringer Ingelheim), Consultant and speaker (Santen, Bayer, Senju, Boehringer Ingelheim, MSD, Chugai, Hoya, Novartis, Nikon TBC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. The study was approved by an ethics committee at each study center (Kansai Medical University Hospital: 2021267; Toyama University: R2021136; University of Yamanashi Hospital: 2553; Yokohama City University: F220600027; Jichi Medical University: 22-034; Chofu Eye Clinic: LIN08548; Nihon University Hospital: 20220109; Gumna University Hospital: IRB2021-055(1946)). Patient consent: All subjects provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}